Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Brian Lawlor, Ricardo Segurado, Sean Kennelly, Marcel G. M. Olde Rikkert, Robert Howard, Florence Pasquier, Anne Borjesson-Hanson, Magda Tsolaki, Ugo Lucca, D. William Molloyid, Robert Coen, Matthias W. Riepe, Janos Kalman, Rose Anne Kenny, Fiona Cregg, Sarah O'Dwyer, Cathal Walsh, Jessica Adams, Rita Banzi, Laetitia BreuilhLeslie Daly, Suzanne Hendrix, Paul Aisen, Siobhan Gaynor, Ali Sheikhi, Diana G. Taekema, Frans R. Verhey, Raffaello Nemni, Flavio Nobili, Massimo Franceschi, Giovanni Frisoni, Orazio Zanetti, Anastasia Konsta, Orologas Anastasios, Styliani Nenopoulou, Fani Tsolaki-Tagaraki, Magdolna Pakaski, Olivier Dereeper, Vincent de la Sayette, Olivier Senechal, Isabelle Lavenu, Agnes Devendeville, Gauthier Calais, Fiona Crawford, Michael Mullan, NILVAD Study Grp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere1002660
Number of pages20
JournalPLoS Medicine
Volume15
Issue number9
DOIs
Publication statusPublished - 1 Sep 2018

Keywords

  • COGNITIVE DECLINE
  • DEMENTIA
  • PREVENTION
  • NEUROPATHOLOGY
  • HYPERTENSION
  • BLOCKERS

Cite this

Lawlor, B., Segurado, R., Kennelly, S., Rikkert, M. G. M. O., Howard, R., Pasquier, F., Borjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloyid, D. W., Coen, R., Riepe, M. W., Kalman, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., ... NILVAD Study Grp (2018). Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 15(9), [e1002660]. https://doi.org/10.1371/journal.pmed.1002660